Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edecesertib in Cutaneous Lupus Erythematosus (COSMIC)
NCT05629208Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Countries
- 3
01
Overview
A Phase 2 trial of edecesertib in cutaneous lupus erythematosus (CLE), sponsored by Gilead Sciences. Started Apr 2023; status: terminated.
02
Drugs
edecesertib
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT05629208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629208.